Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (201-210 of 280) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic study of the novel antitumor agent SR233377P M LoRusso, B J Foster, A Wozniak, et al.
Cancer|September 14, 2012
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanomaSapna P Patel, Alexander J Lazar, Nicholas E Papadopoulos, et al.
Cancer Research Communications|May 12, 2025
First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid TumorsBenedito A Carneiro, Olumide B Gbolahan, Albiruni Abdul Abdul Razak, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumorsToshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
British Journal of Cancer|March 23, 2016
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignanciesJoaquin Mateo, David Olmos, Herlinde Dumez, et al.
Scientific Reports|May 25, 2021
Improved methods for RNAseq-based alternative splicing analysisRebecca F Halperin, Apurva Hegde, Jessica D Lang, et al.
Nature Neuroscience|December 22, 1999
A cultural effect on brain functionE Paulesu, E McCrory, F Fazio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432Patricia M LoRusso, Karthik Venkatakrishnan, Ramesh K Ramanathan, et al.
Pageof 28

Showing results (201-210 of 280) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic study of the novel antitumor agent SR233377P M LoRusso, B J Foster, A Wozniak, et al.
Cancer|September 14, 2012
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanomaSapna P Patel, Alexander J Lazar, Nicholas E Papadopoulos, et al.
Cancer Research Communications|May 12, 2025
First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid TumorsBenedito A Carneiro, Olumide B Gbolahan, Albiruni Abdul Abdul Razak, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumorsToshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
British Journal of Cancer|March 23, 2016
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignanciesJoaquin Mateo, David Olmos, Herlinde Dumez, et al.
Scientific Reports|May 25, 2021
Improved methods for RNAseq-based alternative splicing analysisRebecca F Halperin, Apurva Hegde, Jessica D Lang, et al.
Nature Neuroscience|December 22, 1999
A cultural effect on brain functionE Paulesu, E McCrory, F Fazio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432Patricia M LoRusso, Karthik Venkatakrishnan, Ramesh K Ramanathan, et al.
Pageof 28